Table 2.
Antiretroviral strategies used at baseline in the 52 patients who switched to DBLR
| ARV regimen at baseline (before patients switched to DBLR) | Active ARV drugs at baseline | Number of patients who switched to dolutegravir associated with another ARV | Number of patients who switched to dolutegravir monotherapy |
|---|---|---|---|
| 1 EI + 1 INI | 2 | 1 | |
| 1 EI + 1 PI/r | 2 | 1 | |
| 1 INI + 1 NNRTI | 2 | 3 | 1 |
| 1 INI + 1 NRTI | 2 | 1 | |
| 1 INI + 1 PI | 2 | 3 | 2 |
| 1 INI + 1 PI/r | 2 | 5 | |
| 2 NRTI | 2 | 2 | |
| 2 PI/r | 2 | 1 | |
| 1 EI + 1 INI + 1 NNRTI | 3 | 1 | |
| 1 EI + 2 NRTI | 3 | 1 | |
| 1 INI + 1 NRTI + 1 NNRTI | 3 | 1 | |
| 1 INI + 2 NRTI | 3 | 5 | 9 |
| 1 INI + 2 PI/r | 3 | 1 | |
| 2 NRTI + 1 NNRTI | 3 | 1 | 6 |
| 2 NRTI + 1 PI | 3 | 2 | |
| 2 NRTI + 1 PI/r | 3 | 3 | |
| 1 INI + 2 NRTI + 1 NNRTI | 4 | 1 | |
| 1 INI + 2 NRTI + 1 PI/r | 4 | 1 |
ARV, antiretroviral; EI, entry inhibitor.